Rosiglitazone stimulates the release and synthesis of insulin by enhancing GLUT-2, glucokinase and BETA2/NeuroD expression

Biochemical and Biophysical Research Communications

Volumn 367, Issue 3, 2008, Pages 623-629

  Kim, Hyo Sup ^a   Noh, Jung Hyun ^b   Hong, Seung Hyun ^a   Hwang, You Cheol ^a   Yang, Tae Young ^a   Lee, Myung Shik ^a   Kim, Kwang Won ^a   Lee, Moon Kyu ^a  

^a Samsung Medical Center   (South Korea)

^b Inje University College of Medicine   (South Korea)

Author keywords

BETA2 NeuroD; Glucokinase (GCK); Glucose stimulated insulin release (GSIR); GLUT 2; Insulin synthesis; PPAR ; Rosiglitazone (RGZ)

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; BETA 2 ADRENERGIC RECEPTOR; GLUCOKINASE; GLUCOSE TRANSPORTER 2; INSULIN; NEUROGENIC DIFFERENTIATION FACTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; ROSIGLITAZONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CALCIUM CELL LEVEL; CONTROLLED STUDY; DRUG ANTAGONISM; GENE EXPRESSION; INSULIN RELEASE; INSULIN SYNTHESIS; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION;

ANILIDES; ANIMALS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CELLS, CULTURED; GLUCOKINASE; GLUCOSE; GLUCOSE TRANSPORTER TYPE 2; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN-SECRETING CELLS; INSULINOMA; MALE; NERVE TISSUE PROTEINS; PPAR GAMMA; RATS; RATS, INBRED OLETF; THIAZOLIDINEDIONES; UP-REGULATION;

EID: 38649115669     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2007.12.192     Document Type: Article

References (35)

1. Auwerx J. PPAR-γ, the ultimate thrifty gene. Diabetologia 42 (1999) 1033-1049
2. Vamecq J., and Latruffe N. Medical significance of peroxisome proliferator-activated receptors. Lancet 354 (1999) 141-148
3. Welters H.J., McBain S.C., Tadayyon M., Scarpello J.H., Smith S.A., and Morgan N.G. Expression and functional activity of PPAR-γ in pancreatic β-cells. Br. J. Pharmacol. 142 (2004) 162-170
4. Fujiwara T., Yoshioka S., Yoshioka T., Ushiyama I., and Horikoshi H. Characterization of new oral antidiabetic agent CS-045. Diabetes 37 (1988) 1549-1558
5. Nolan J.J., Ludvik B., Beerdsen P., Joyce M., and Olefsky J. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N. Engl. J. med. 331 (1994) 1188-1193
6. Matsuda K., Okamoto Y., Tsuura Y., Kato S., Miura T., Tsuda K., Horikoshi H., Ishida H., and Seino Y. Effects of troglitazone (CS-045) on insulin secretion in isolated rat pancreatic islets and HIT cells: an insulinotropic mechanism distinct from glibenclamide. Diabetologia 38 (1995) 24-30
7. Colca J.R., Wyse B.M., Sawada G., Jodelis K.S., Connell C.L., Fletcher-McGruder B.L., and Palazuk B.J. Ciglitazone, a hyperglycemic agent: early effects on the pancreatic islets of ob/ob mice. Metabolism 37 (1988) 276-280
8. Fujiwara T., Wada M., and Fukami M. Characterization of CS-045, a new oral antidiabetic agents, II. Effects on glycemic control and pancreatic islet structure at a late stage of the diabetic syndrome in C57 BL/KsJ-db/db mice. Metabolism 40 (1991) 1213-1218
9. Leesnitzer L.M., Parks D.J., Bledsoe R.K., Cobb J.E., Collins J.L., Consler T.G., Davis R.G., Hull-Ryde E.A., Lenhard J.M., Patel L., Plunket K.D., Shenk J.L., Stimmel J.B., Therapontos C., Willson T.M., and Blanchard S.G. Functional consequences of cysteine modification in the ligand binding sites of peroxisome proliferator activated receptors by GW9662. Biochemistry 41 (2002) 6640-6650
10. Kelley D.E., and Goodpaster B.H. Skeletal muscle triglyceride: an aspect of regional adiposity and insulin resistance. Diabetes Care 24 (2001) 933-941
11. Furnsinn C., and Waldhausl W. Thiazolidinediones: metabolic actions in vitro. Diabetologia 45 (2002) 1211-1223
12. Yu J.G., Javorschi S., Hevener A.L., Kruszynska Y.T., Norman R.A., Sinha M., and Olefsky J.M. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. Diabetes 51 (2002) 2968-2974
13. Yamauchi T., Kamon J., Waki H., Terauchi Y., Kubota N., Hara K., Mori Y., Ide T., Murakami K., Tsuboyama-Kasaoka N., Ezaki O., Akanuma Y., Gavrilova O., Vinson C., Retiman M.L., Kagechika H., Shudo K., Yoda M., Nakano Y., Tobe K., Nagai R., Kimura S., Tomita M., Froguel P., and Kadowaki T. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat. Med. 7 (2001) 941-946
14. Weinstein S.P., Holand A., O'Boyle E., and Haber R.S. Effects of thiazolidinediones on glucose-induced insulin resistance and GLUT4 glucose transporter expression in rat skeletal muscle. Metabolism 42 (1993) 1365-1369
15. Ciaraldi T.P., Glimore A., Olefsky J.M., Goldberg M., and Heidenreich K.A. In vitro studies on the action of CS-045, a new anti-diabetic agent. Metabolism 39 (1990) 1056-1062
16. Kim H.I., Kim J.W., Kim S.H., Cha J.Y., Kim K.S., and Ahn Y.H. Identification and functional characterization of the peroxisomal proliferator response element in rat GLUT2 promoter. Diabetes 49 (2000) 1517-1524
17. Kim H.I., Cha J.Y., Kim S.Y., Kim J.W., Roh K.J., Seong J.K., Lee N.T., Choi K.Y., Kim K.S., and Ahn Y.H. Peroxisomal proliferator-activated receptor-γ upregulates glucokinase gene expression in β-cells. Diabetes 51 (2002) 676-685
18. Sharma A., Moore M., Marcora E., Lee J.E., Qiu Y., Samaras S., and Stein R. The NeuroD1/BETA2 sequences essential for insulin gene transcription colocalize with those necessary for neurogenesis and p300/CREB binding protein binding. Mol. Cell. Biol. 19 (1999) 704-713
19. Dumonteil E., Laser B., Constant I., and Philippe J. Differential regulation of the glucagon and insulin I gene promoters by the basic helix-loop-helix transcription factors E47 and BETA2. J .Biol. Chem. 273 (1998) 19945-19954
20. Qiu Y., Sharma A., and Stein R. p300 mediates transcriptional stimulation by the basic helix-loop-helix activators of the insulin gene. Mol. Cell. Biol. 18 (1998) 2957-2964
21. Qiu Y., Guo M., Huang S., and Stein R. Insulin gene transcription is mediated by interactions between the p300 coactivator and PDX-1, BETA2, and E47. Mol. Cell. Biol. 22 (2002) 412-420
22. Naya F.J., Huang H.P., Qiu Y., Mutoh H., DeMayo F.J., Leiter A.B., and Tsai M.J. Diabetes, defective pancreatic morphogenesis, and abnormal enteroendocrine differentiation in BETA2/neuroD-deficient mice. Genes Dev. 11 (1997) 2323-2334
23. Cordle S.R., Henderson E., Masucha H., Weil P.A., and Stein R. Pancreatic β-cell-type-specific transcription of the insulin gene is mediated by basic helix-loop-helix DNA-binding proteins. Mol. Cell. Biol. 11 (1991) 1734-1738
24. Moates J.M., Nanda S., Cissell M.A., Tsai M.J., and Stein R. BETA2 activates transcription from the upstream glucokinase gene promoter in islet β-cells and gut endocrine cells. Diabetes 52 (2003) 403-408
25. Chu K., and Tsai M.J. Neuronatin, a downstream target of BETA2/NeuroD1 in the pancreas, is involved in glucose-mediated insulin secretion. Diabetes 54 (2005) 1064-1073
26. Ohneda K., Mirmira R.G., Wang J., Johnson J.D., and German M.S. The homeodomain of PDX-1 mediates multiple protein-protein interactions in the formation of a transcriptional activation complex on the insulin promoter. Mol. Cell. Biol. 20 (2000) 900-911
27. Moibi J.A., Gupta D., Jetton T.L., Peshavaria M., Desai R., and Leahy J.L. Peroxisome proliferator-activated receptor-γ regulates expression of PDX-1 and NKX6.1 in INS-1 cells. Diabetes 56 (2007) 88-95
28. Gupta D., Peshavaria M., Jetton J.L., Desai R., and Leahy J.L. Transcriptional regulation of PDX-1 by PPAR-γ in islet β-cells (Abstract). Diabetes 55 Suppl. 1 (2006) A366
29. Glauser D.A., and Schlegel W. The emerging role of FOXO transcription factors in pancreatic β-cells. J. Endocrinol. 193 (2007) 195-207
30. Kitamura T., Nakae J., Kitamura Y., Kido Y., Biggs III W.H., Wright C.V., White M.F., Arden K.C., and Accili D. The forkhead transcription factor Foxo1 links insulin signaling to Pdx1 regulation of pancreatic β-cell growth. J. Clin. Invest. 110 (2002) 1839-1847
31. Kitamura Y.I., Kitamura T., Kruse J.P., Raum J.C., Stein R., Gu W., and Accili D. FoxO1 protects against pancreatic β-cell failure through NeuroD and MafA induction. Cell Metab. 2 (2005) 153-163
32. Dowell P., Otto T.C., Adi S., and Lane M.D. Convergence of peroxisome proliferator-activated receptor-γ and Foxo1 signaling pathways. J. Biol. Chem. 278 (2003) 45485-45491
33. Shimabukuro M., Zhou Y.T., Lee Y., and Unger R.H. Troglitazone lowers islet fat and restores β-cell function of Zucker diabetic fatty rats. J. Biol. Chem. 273 (1998) 3547-3550
34. Hevener A.L., Reichart D., Janez A., and Olefsky J. Thiazolidinedione treatment prevents free fatty acid-induced insulin resistance in male Wistar rats. Diabetes 50 (2001) 2316-2322
35. Koh E.H., Kim M.S., Park J.Y., Kim H.S., Youn J.Y., Park H.S., Youn J.H., and Lee K.U. Peroxisome proliferator-activated receptor (PPAR)-α activation prevents diabetes in OLETF rats: comparison with PPAR-γ activation. Diabetes 52 (2003) 2331-2337